AnaptysBio and GSK Receive FDA Label Expansion for Jemperli in Rectal Cancer
AnaptysBio (ANAB) saw its stock rise after GlaxoSmithKline (GSK) announced the U.S. Food and Drug Administration approved a label expansion for their anti-PD-1 therapy, Jemperli. The approval allows the drug to be used in treating a specific type of rectal cancer under an accelerated pathway. This regulatory update marks progress for both AnaptysBio and GSK as they expand the therapeutic applications of Jemperli. The label expansion could increase market access and usage, potentially boosting sales and investor confidence.
Topics: biotech cancer therapy pd-1 inhibitor
Read the full article at Seeking Alpha
Part of the story Gilead Sciences Receives Multiple FDA Approvals and Label Expansions (2 articles)